Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
96 participants
INTERVENTIONAL
2019-11-21
2021-04-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Acetylcysteine Against Acute Renal Insult During Cardiopulmonary Bypass.
NCT00190034
A Study of The Effectiveness of N-Acetylcysteine in Kidney Protection Following Cardiopulmonary Bypass
NCT00187330
Intravenous Amino Acid Therapy for Kidney Protection in Cardiac Surgery.
NCT03709264
Effect of the Amino Acid L-arginine on Perioperative Cardio-vascular Risk in Non-selected Patients
NCT01413815
Effects of Endothelin Receptor Antagonist on Ischemic Kidney Injury During Nephron Sparing Surgery
NCT04450095
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Papaverine group
Immediately after the renal artery declamping, papaverine 30 mg (1 ample, 1 ml) is mixed with 5 ml of normal saline (total 6 ml) and sprinkled around the renal artery.
Papaverine
Immediately after the renal artery declamping, papaverine 30 mg (1 ample, 1 ml) is mixed with 5 ml of normal saline (total 6 ml) and sprinkled around the renal artery.
Normal saline group
Immediately after the renal artery declamping, normal saline 6 ml is sprinkled around the renal artery.
Normal saline
Immediately after the renal artery declamping, normal saline 6 ml is sprinkled around the renal artery.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Papaverine
Immediately after the renal artery declamping, papaverine 30 mg (1 ample, 1 ml) is mixed with 5 ml of normal saline (total 6 ml) and sprinkled around the renal artery.
Normal saline
Immediately after the renal artery declamping, normal saline 6 ml is sprinkled around the renal artery.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients undergoing robot assisted partial nephrectomy under general anesthesia
* 20 years old ≤ age \<80 years old
* Patients who voluntarily agreed to this clinical study
* eGFR ≥ 60 ml / min / 1.73 m2 (Chronic Kidney Disease Epidemiology Patients with Collaboration)
Exclusion Criteria
* Multiple renal mass
* If the surgery plan is changed due to open
* When surgery is performed together with other surgery
* Multiple renal artery
* Patients with hypersensitivity to papaverine
* Patients with atrioventricular block
* Pregnant and lactating women
* Patients using levodopa
* Refusal of patient
20 Years
79 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Asan Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Young-Kug Kim, MD
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Young-Kug Kim, MD,PhD
Role: PRINCIPAL_INVESTIGATOR
Asan Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Asan medical Center
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20191111
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.